GlaxoSmithKline Pharmaceuticals share news, announcements and annual reports
NSE: GLAXOBSE: 500660Pharmaceuticals & BiotechnologyMid Cap
GlaxoSmithKline Pharmaceuticals Limited · Formerly Glaxo (India) · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 1969 on BSE, Dec 2000 on NSE
Last close ₹2,494.30down ₹20.80 (0.83%)BSE ₹2,483.55
Share price at the NSE close on 30 Oct 2026. Previous close ₹2,515.10.
30 Oct: open ₹2,527.60, high ₹2,528.90, low ₹2,479.30
52-week range of traded prices to 30 Oct 2026
₹2,088.10Low, 12 Jun 2026₹3,120.70High, 28 Aug 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹42,255 Cr221st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 39.56
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 18.64
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.29%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 50.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 56.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 56,34965.0% delivered
GlaxoSmithKline Pharmaceuticals share news and announcements
719 announcements, routine notices left out, newest first. Page 12 of 15.
May 2015
18 May · Dividend
Board of Directors of the Company at its meeting held on May 18, 2015 have recommended the payment of a Dividend of Rs. 62.50 per equity share for the fifteen month period ended March 31, 2015. The dividend if approved by the shareholders will be paid on or after August 01, 2015.
Apr 2015
Mar 2015
26 Mar · Disclosure of Voting Pattern - Clause 35A
Feb 2015
Jan 2015
Dec 2014
24 Dec · Legal
Exchange had sought clarification from GlaxoSmithKline Pharmaceuticals Limited with respect to a news item captioned "CCI Gives Approval for Novartis-GSK Pharma Deal". The Company has clarified that "The Competition Commission of India has approved the GSK - Novartis deal relates to the global deal between GlaxoSmithKline Plc ( GSK Plc ) and Novartis AG ( Novartis ). GSK Plc, an entity situated in UK indirectly holds shares of GlaxoSmithKline Pharmaceuticals Limited ( GSK India ) and GSK India has not accepted any binding commitments in relation to the global deal. No filings and / or representations have been made by GSK India in the application for the approval filed by GSK Plc and Novartis. GSK India shall make all necessary disclosures as and when any obligation to do so arises under clause 36 of the listing agreement".24 Dec · Legal
Exchange has sought clarification from GlaxoSmithKline Pharmaceuticals Limited with respect to recent news item captioned "CCI Gives Approval for Novartis-GSK Pharma Deal". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Nov 2014
12 Nov · News Verification
News Verification : The media had reports that "GSK Pharma Shortlists Buyers For Rs 1,000 Cr Thane Property". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. GlaxoSmithKline Pharmaceuticals Limited has vide its letter inter-alia stated," The said information is incorrect and the Company has not shortlisted any buyer."7 Nov · Change in Financial Year
Board of Directors of the Company at its meeting held on November 6, 2014, decided to change the financial year of the Company from January - December to April - March. Accordingly the Company's current financial year shall be for a period of fifteen months i.e. from January 1, 2014 to March 31, 2015.
Oct 2014
9 Oct · Board meeting
To consider amongst other things, approval of unaudited financial results for the quarter ended September 30, 2014.
Aug 2014
Jul 2014
May 2014
Apr 2014
21 Apr · Disclosure of Voting Pattern - Clause 35A
17 Apr · Results
Mar 2014
Feb 2014
18 Feb · Dividend
Dividend will be payable on or after April 19, 2014.18 Feb · Corporate action
Company has fixed Book Closure from April 7, 2014 to April 17, 2014 for the purpose of payment of Dividend18 Feb · Dividend
Board of Directors of the Company at its meeting held on February 18, 2014 have recommended the payment of a Dividend of Rs. 50/- per equity share for the year ended December 31, 2013.
Jan 2014
Dec 2013
11 Dec · Updates
GlaxoSmithKline Pharmaceuticals Limited had informed the Exchange that: "It has come to our knowledge that in the major pockets of the country our products are not being purchased by the trade from September 15, 2013. On account of the above, sales of the Company continue to be affected". The Company has now informed the Exchange that the trade has resumed the purchase of the Company's products across the country since last week of November 2013.
Nov 2013
11 Nov · Results
11 Nov · Results
Standalone Results for the quarter ended on 30-SEP-2013 as follows: Net Sales of Rs. 62054 lacs for the quarter ending on 30-SEP-2013 against Rs. 63686 lacs and Rs. 66850 lacs for the quarters ending on 30-JUN-2013 and 30-SEP-2012 respectively. Net Profit / (Loss) of Rs. 10095 lacs for the quarter ending on 30-SEP-2013 against Rs. 11504 lacs and Rs. 15234 lacs for the quarters ending on 30-JUN-2013 and 30-SEP-2012 respectively.
Oct 2013
25 Oct · Board meeting
To consider amongst other things, approval of unaudited financial results for the quarter ended September 30, 2013.8 Oct · Updates
It has come to our knowledge that in the major pockets of the country our products are not being purchased by the trade from September 15, 2013. On account of the above, sales of the Company continue to be affected
Aug 2013
Jul 2013
22 Jul · Board meeting
Inter-alia, to consider amongst other things, approval of unaudited financial results for the quarter April-June 2013 (Q2) and half-year January-June 2013.
Jun 2013
4 Jun · News Verification
News Verification : The media had reports that GlaxoSmithKline Plc is in the process to increase the stake in GlaxoSmithKline Pharmaceuticals Limited through open offer. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. GlaxoSmithKline Pharmaceuticals Limited has vide its letter inter-alia stated, " The report is speculative in nature and it is the Company's policy not to comment on market speculation."